The Briefing
- New urine test detects bladder cancer accurately.
- Home testing reduces invasive hospital procedures.
- Finland doctoral pilot produces first graduate.
Lauri Ryyppö has become the first researcher to graduate from Tampere University under Finland’s national doctoral training pilot, developing a 25-gene urine test that identifies urothelial cancer with 95 percent accuracy.
According the University of Tampere, Ryyppö conducted his research within the Precision Cancer Medicine pilot, focusing on ovarian and urothelial cancers that present significant clinical challenges.
Traditional monitoring for urothelial cancer, which most commonly manifests as bladder cancer, requires frequent and invasive cystoscopy procedures.
The newly developed UroScout urine test successfully detected 95 percent of urothelial cancer cases at diagnosis, including early-stage tumors that are typically difficult to identify.
In addition to the urine test, Ryyppö investigated blood plasma tests that identified ovarian cancer recurrence approximately six months earlier than current monitoring methods.
Ryyppö noted in a report published by the university that the guaranteed funding eliminated the financial uncertainty of short-term contracts and allowed him to focus entirely on his scientific work.
Ryyppö was part of the national doctoral training pilot, which runs across Finland from 2024 to 2027, providing secure three-year employment contracts designed to support doctoral researchers.
Ryyppö noted in a report published by the university that the guaranteed funding eliminated the financial uncertainty of short-term contracts and allowed him to focus entirely on his scientific work.
The innovation offers major practical benefits for patients, who can collect samples at home rather than traveling to specialized medical facilities.
By replacing routine hospital visits with home testing, the method significantly reduces public healthcare expenditures and patient burdens.
Finland’s social insurance institution covers specialized patient transport costs, meaning home testing also reduces public transit reimbursements funded by the state.
Ryyppö is currently participating in the international UROSCOUT-1 study across Finland, Japan, and Canada to further validate the test with six hundred participants.
With rapid advancements in DNA sequencing, the test could potentially enter clinical patient use within the next few years.
Submit Form
